Wellnex Life reports 22% sales growth in Q4 FY25

Published 31/07/2025, 07:36
Wellnex Life reports 22% sales growth in Q4 FY25

SYDNEY - Wellnex Life Limited (ASX/AIM:WNX) reported sales of $6.6 million for the fourth quarter of fiscal year 2025, representing a 22.2% increase compared to the previous quarter, according to a quarterly report released Thursday.

The health and wellness company recorded cash receipts of $6.5 million for the quarter ended June 30, 2025, in line with the previous quarter’s $6.6 million. Wellnex achieved positive net cash flow from operations of $0.98 million, a significant improvement from $0.04 million in the third quarter.

Brand sales rose 19.5% to $4.9 million, while IP licensing revenue increased 30.8% to $1.7 million compared to the previous quarter.

The company reported improved gross margins in the second half of FY25, reaching 37% ($4.4 million) compared to 23% ($2.7 million) in the first half of the fiscal year.

Wellnex has secured additional debt funding of $2.825 million through a loan facility with Reach Wholesale to support margin enhancement initiatives and business growth. The 24-month facility carries a 14% interest rate and is secured over assets of the group’s key subsidiaries.

As part of this financing arrangement, Jeffrey Yeh, a non-executive director of Wellnex, is subscribing $825,000 to the facility.

The company has also reduced its maximum commitment with ScotPac to $3.8 million from $5.5 million, with approximately $1.1 million currently remaining available.

Wellnex stated it has commenced an internal review of operations to identify key brand assets for medium to long-term investment, aiming to maximize revenue, margins and operational profitability. As part of this review, the company divested The Iron Company assets on June 30, 2025.

Based on a press release statement, the company implemented several margin enhancement initiatives during the quarter, including purchasing extended supply of stock for one of its leading brands at a targeted saving exceeding 25%.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.